NASDAQ: ERAS

Guangzhou Jiayue Pharmaceutical Technology Co., Ltd, a Chinese pharmaceutical company, has entered into a licensing agreement with Erasca (NASDAQ: ERAS), a US-based biopharmaceutical company. Under the terms of this agreement, Erasca has been granted exclusive rights to research, develop, and commercialize Jiayue Pharma’s pan-RAS (ON) inhibitor, JYP0015, excluding China mainland,…